ahkona
b
mcmichael
j
webster
r
g
immun
respons
influenza
virus
problem
protect
infect
basic
appli
resealch
ed
p
bear
crc
press
boca
raton
pp
austrian
r
gold
j
pneumococc
bacteremia
especi
refer
becterem
pneumococc
pneumonia
ann
lnrern
med
benson
c
e
sweeney
c
r
isol
srepro
ocru
pneumoriru
type
equin
speci
j
clin
miwohiol
bienenstock
j
c
e
ro
befu
oneil
common
mucos
immunolog
system
involv
bronchu
breast
bowel
ad
eip
med
b
pneumococc
plysaccharid
immunol
braleymulen
h
requir
foractiv
contrasuppressor
cell
type
bndge
c
g
edington
n
genet
restrict
cytolysi
follow
like
mammal
hors
evolv
complex
combin
nonspecif
specif
defenc
system
combat
wide
varieti
parasit
infecti
agent
equin
ontogeni
reveal
essenti
featur
matur
immun
system
establish
week
foetu
maintain
within
steril
environ
penyman
mcguir
torbeck
matur
equin
foetal
immun
respons
shown
product
antibodi
antigen
challeng
utero
live
attenu
venezuelan
equin
encephalomyel
vaccin
xenogen
erythrocyt
morgan
bryan
mock
mock
morgan
jochin
lock
recent
studi
shown
high
level
antibodi
specif
cellular
immun
respons
gener
protein
antigen
immunis
equin
foetu
hannant
et
ul
potenti
matur
immun
respons
equin
foetu
could
explain
occasion
find
pathogenspecif
antibodi
foetal
circul
foetus
abort
noninfecti
reason
whitwel
bowen
hannant
opportun
transfer
matern
immunoglobulin
equin
foetu
prepartum
foal
deliv
immunolog
naiv
term
mock
er
ul
contamin
environ
immedi
protect
infecti
organ
usual
achiev
uptak
maternallyderiv
immunoglobulin
colostrum
sourc
passiv
immun
combin
physic
barrier
infect
nonspecif
innat
immunolog
respons
gener
suffici
allow
foal
surviv
develop
specif
primari
immunolog
respons
first
week
life
howev
passiv
acquir
activ
achiev
immunolog
mechan
young
foal
alway
suffici
prevent
infecti
agent
becom
establish
otherwis
healthi
individu
success
infecti
agent
caus
diseas
relat
immunolog
statu
host
capac
invad
organ
avoid
immunolog
attack
purpos
articl
summaris
current
knowledg
equin
immun
respons
infecti
agent
highlight
aspect
relat
protect
recoveri
infect
necess
much
immunolog
work
equin
infecti
diseas
focuss
common
respiratori
pathogen
ubiquit
agent
within
hors
popul
caus
high
mortal
result
consider
econom
loss
perform
breed
industri
affect
recreat
pursuit
hors
poni
owner
although
consider
expertis
appli
molecular
biolog
genet
antigen
analys
import
agent
equin
infecti
diseas
equid
herpesviru
arter
viru
influenza
viru
african
hors
sick
infecti
anaemia
streptoc
oc
cx
c
q
u
powel
recent
similar
input
fundament
immunobiolog
hors
fortun
recent
advanc
molecular
cellular
biolog
provid
tool
research
ask
specif
question
function
equin
immun
respons
target
immunoprophylact
procedur
favour
stimul
respons
protect
broad
field
equin
immunolog
review
accompani
articl
morrison
p
reader
refer
specif
explan
cellular
immun
respons
control
mechan
simpl
term
immunolog
reaction
divid
two
type
humor
cell
mediat
immun
respons
humor
respons
mediat
antibodi
molecul
immunoglobulin
sccrete
b
lymphocyt
interact
directli
antigen
form
respons
stimul
solubl
particul
includ
cellassoci
antigen
process
spleen
lymph
node
earli
interest
equin
immunoglobulin
stimul
year
ago
use
hyperimmun
equin
antisera
bacteria
bacteri
toxin
treatment
prophylaxi
human
diseas
classif
equin
immunoglobulin
rather
conflict
succeed
year
current
consensu
support
design
seven
antigen
distinct
group
four
group
immunoglobulin
consid
igg
subcl
iggc
igg
other
repres
igm
iga
ige
mcguir
crawford
henson
suter
fey
biochem
properti
equin
immunoglobulin
review
montgomeri
cellmedi
immun
cmi
characteris
induct
cytolyt
helper
lymphocyt
subset
restrict
classi
major
histocompat
complex
mhc
gene
product
zinkernagel
doherti
mhc
express
restrict
cell
specialis
antigen
present
function
cell
activ
intlammatori
stimuli
whcrea
classi
mhc
molecul
express
cell
cmi
humor
immun
respons
control
specialis
lymphoid
cell
cytokin
product
interleukin
interferon
see
morrison
p
primari
site
infect
replic
respiratori
pathogen
upper
respiratori
tract
nasopharynx
trachea
lower
airway
import
understand
site
effect
immun
respons
must
function
infect
system
spread
prevent
accumul
evid
humor
cellular
immun
respons
stimul
hors
natur
experiment
infect
respiratori
pathogen
clear
howev
role
play
type
immun
respons
protect
common
find
particular
antibodi
respons
gener
infect
progress
increas
circul
antibodi
often
coincid
reduct
clinic
sign
diseas
tempt
infer
antibodi
neutralis
progress
infect
sometim
unfortun
assum
antibodi
sogener
protect
hors
infect
clearli
rational
faulti
take
account
contribut
type
antibodi
eg
secret
directli
respiratori
mucos
surfac
cellular
immun
respons
becom
appar
number
altern
rout
exist
infect
cell
process
degrad
microbi
antigen
affect
markedli
immun
respons
gener
weiss
bogen
exampl
common
premis
infect
pathogen
stimul
much
higher
level
immun
exposur
inactiv
antigen
level
cytotox
effector
memori
lymphocyt
much
higher
infect
exposur
influenza
virus
immunis
inactiv
whole
viru
turn
effect
stimul
immun
viru
subunit
antigen
askona
mcmichael
webster
gradat
immun
produc
larg
function
method
viru
antigen
process
deliv
lymphocyt
detail
antigen
process
stimul
immun
effector
cell
found
momson
review
p
brief
infect
live
viru
usual
result
endogen
process
viral
antigen
stimul
mhc
classi
restrict
cytotox
effector
cell
bear
surfac
marker
phenotyp
outcom
interact
cytolyt
damag
infect
target
cell
randal
souberbiel
exogen
process
microbi
antigen
eg
phagocytosi
virionsbacteria
partial
degrad
antigen
usual
result
stimul
respond
cell
restrict
mhc
element
process
cell
lymphocyt
show
restrict
express
surfac
marker
type
phenotyp
helper
cell
gay
et
import
local
amplif
cellular
humor
immun
respons
stimul
memori
lymphocyt
exampl
cytotox
effector
cell
show
typic
surfac
phenotyp
antigen
specif
identifi
influenza
momson
p
compris
domin
cytotox
cell
herp
simplex
infect
speci
schmid
third
group
antigen
specif
cytotox
lymphocyt
describ
function
without
genet
restrict
cell
characteris
special
natur
receptor
antigen
term
gammadelta
cell
receptor
janeway
jone
hayday
describ
hors
phenotyp
evid
may
stimul
equin
influenza
infect
clearli
initi
immun
respons
site
infect
complex
featur
begin
understood
point
way
identifi
respons
like
import
effect
immun
describ
best
consid
equin
immun
respons
common
respiratori
pathogen
close
relationship
antibodi
respons
mucos
surfac
mani
follow
observ
appropri
studi
immun
respons
alimentari
genit
tract
typic
clinic
sign
equin
influenza
seen
infecti
outbreak
pyrexia
cough
sever
case
dyspnoea
anorexia
reproduc
experiment
mumford
hannant
jessett
sever
clinic
sign
level
nasopharyng
shed
viru
relat
infecti
viru
dose
provid
good
control
experiment
system
evalu
immun
respons
earli
inform
durat
natur
immun
immun
stimul
experiment
infect
equin
influenza
virus
suggest
high
level
antibodi
requir
protect
rous
ditchfield
kumanomido
akyama
find
accord
studi
vaccineinduc
immun
kumanomido
akiyama
mumford
et
contrast
rechalleng
experi
poni
previous
infect
influenza
show
recent
expos
anim
high
level
antibodi
poni
low
level
antibodi
infect
week
previous
protect
hannant
et
observ
highlight
import
differ
infectioninduc
immun
provid
convent
inactiv
v
vaccin
clinic
immun
correl
strongli
level
circul
antibodi
viru
haemagglutinin
wood
et
mumford
et
mumford
wood
folker
schild
similar
find
made
human
influenza
potent
immun
reinfect
establish
natur
experimentallyinduc
primari
infect
johnson
et
last
sever
year
fact
ada
jone
suggest
cell
memori
human
influenza
could
maintain
year
howev
consid
durat
immun
import
differenti
demonstr
immunolog
memori
vitro
test
immunolog
mediat
protect
second
infect
shown
prime
individu
primari
site
viru
replic
nasopharynx
trachea
lower
airway
necessari
consid
contribut
local
antibodi
cell
mediat
respons
equin
influenza
anim
immunis
previou
infect
welldevelop
mucos
immun
system
describ
hors
mair
batten
stoke
bourn
antibodi
detect
respiratori
secret
clinic
normal
hors
mair
stoke
bourn
difficult
ascrib
function
signific
nasopharyng
antibodi
equin
influenza
although
stimul
infect
rous
ditchfield
kumanomida
akyama
direct
evid
show
local
antibodi
protect
isol
high
background
level
serum
antibodi
independ
local
circul
antibodi
respons
equin
influenza
infer
differ
kinet
howev
anim
protect
infect
show
unusu
high
level
nasal
antibodi
prechalleng
although
show
local
antibodi
memori
hannant
jessett
oneil
mumford
difficult
assess
import
local
produc
antibodi
site
tissu
inflamm
featur
infect
transud
serum
antibodi
like
occur
wagner
et
local
antibodi
product
equin
nasopharynx
account
per
cent
total
antibodi
recov
nasal
wash
sampl
influenza
infect
speci
iga
isotyp
longest
durat
hannant
et
system
vaccin
inactiv
whole
viru
vaccin
known
produc
circul
antibodi
hors
frequent
vaccin
requir
achiev
maintain
protect
level
mumford
et
evid
local
antibodi
product
equin
respiratori
tract
intramuscular
vaccin
viru
subunit
vaccin
base
immun
stimul
complex
iscom
morein
et
hannant
et
gener
system
vaccin
stimul
local
immun
respons
poorli
emphasis
need
detail
studi
contribut
local
immun
protect
equin
influenza
one
possibl
approach
develop
vaccin
schedul
favour
stimul
mucos
antibodi
obviou
approach
would
introduc
vaccin
nasopharynx
attempt
stimul
mucosa
directli
exist
common
mucos
immun
system
hors
provid
altern
method
stimul
respiratori
mucos
antibodi
independ
system
serum
antibodi
well
document
intestin
respond
antigen
challeng
product
igacommit
precursor
b
cell
peyer
patch
cell
migrat
via
effer
intestin
lymph
thorac
duct
blood
stream
bienenstock
mcdermott
befu
oneil
antigenspecif
precursor
cell
leav
circul
return
intestin
mucos
site
respiratori
reproduct
tract
pahud
mach
widder
stoke
david
bourn
specif
target
mucos
immun
improv
enhanc
uptak
antigen
mucos
associ
lymphoid
tissu
malt
achiev
use
receptor
mediat
uptak
system
base
cholera
toxin
b
chain
cholera
toxin
known
high
affin
epitheli
cell
membran
gmi
gangliosid
function
introduc
toxic
chain
cell
holmgren
remov
toxic
chain
holotoxin
allow
b
chain
use
specif
mucos
adjuv
target
antigen
malt
type
approach
follow
stimul
mucos
immun
influenza
antigen
speci
liang
lamm
nedrud
protect
rechalleng
demonstr
mucos
stimul
cholera
toxin
adjuv
also
prime
cellular
immun
respons
clark
wilson
william
stoke
recent
studi
shown
oral
present
inactiv
influenza
viru
antigen
contain
approx
pg
viru
haemagglutinin
conjug
cholera
toxin
b
chain
well
toler
poni
stimul
new
synthesi
viru
specif
antibodi
nasopharynx
augment
preexist
antibodi
level
hannant
oneil
j
mumford
unpublish
data
similar
result
obtain
direct
applic
viru
toxin
conjug
intranas
studi
progress
measur
viru
neutralis
activ
local
induc
antibodi
recent
work
show
adjuv
effect
cholera
toxin
affect
individu
strain
variat
immunis
anim
therefor
great
potenti
vaccin
adjuv
genet
divers
anim
hors
hirabayashi
et
stimul
immun
respons
first
site
viru
infect
would
appear
logic
approach
design
immunoprophylact
agent
techniqu
wide
applic
theoret
use
infecti
agent
invad
mucos
surfac
may
particularli
use
agent
stwptocmw
equi
protect
infect
seem
relat
local
rather
system
immun
galan
timoney
b
infect
influenza
deem
produc
best
immun
next
best
approach
use
attenu
live
vaccin
stimul
respiratori
tract
system
immun
system
much
way
one
method
develop
attenu
live
viru
vaccin
show
low
reactogen
high
antigen
activ
natur
host
experiment
vaccin
develop
use
hors
base
success
attenu
vaccin
human
speci
experiment
strain
human
influenza
viru
adapt
grow
low
temperatur
eg
use
live
intranas
vaccin
ghendon
et
vaccin
term
temperaturesensit
coldadapt
mutant
prove
success
stimul
longterm
nasal
iga
antibodi
johnson
et
shown
similar
degre
protect
would
induc
infect
nativ
viru
johnson
et
great
advantag
vaccin
safe
advers
side
effect
studi
live
temperatur
sensit
mutant
influenza
aequi
viru
shown
protect
homolog
viru
challeng
four
week
vaccin
holm
et
evid
durat
immun
potenti
bival
vaccin
contain
aequi
aequi
expect
soon
sever
group
research
work
type
live
attenu
equin
influenza
vaccin
approach
broadli
divid
two
main
area
first
base
use
viru
reassort
carri
import
compon
equin
influenza
viru
envelop
haemagglutinin
neuraminidas
outsid
viru
core
deriv
nonpathogen
avian
influenza
viru
hybrid
virus
capac
attach
infect
equin
cell
viru
replic
much
reduc
howev
reassort
viru
surviv
long
enough
stimul
immun
respons
equin
viru
antigen
hope
protect
challeng
infect
nativ
equin
viru
techniqu
prove
valuabl
anim
model
signific
resist
rechalleng
nativ
viru
demonstr
murphi
et
safeti
aspect
reassort
virus
current
investig
experiment
result
avail
soon
second
type
live
influenza
viru
vaccin
investig
base
premis
viru
could
identifi
produc
strong
immun
respons
hors
eg
vaccinia
possibl
construct
recombin
viru
vaccinia
equin
influenza
viru
would
stimul
strong
immun
latter
vaccinia
viru
equin
influenza
viru
recombin
prepar
test
hors
usa
dale
et
shown
stimul
circul
viru
specif
antibodi
necessari
assess
durat
humor
antibodi
measur
cellular
immun
respons
challeng
experi
undertaken
recent
work
shown
vaccinia
viru
recombin
simian
immunodefici
viru
siv
model
human
immunodefici
viru
induc
sivspecif
cytotox
lymphocyt
viva
zhen
et
major
advanc
field
aid
research
highlight
potenti
vaccinia
viru
recombin
stimul
viru
specif
cellular
immun
poxviru
vector
system
offer
great
potenti
stimul
cellular
humordl
immun
safeti
requir
recombin
vaccin
achiev
expect
provid
good
protect
challeng
immedi
futur
iscombas
subunit
vaccin
equin
influenza
soon
avail
commerci
vaccin
properti
stimul
higher
level
circul
antibodi
longer
durat
convent
inactiv
whole
viru
vaccin
therefor
prime
correctli
hors
requir
less
frequent
booster
inject
equid
herpesviru
ehv
worldwid
distribut
four
type
current
describ
two
recognis
import
thoroughbr
race
breed
industri
fig
type
ehvi
associ
respiratori
diseas
abort
neurolog
condit
vari
incoordin
paralysi
allen
bryan
wherea
type
mainli
associ
respiratori
diseas
patel
edington
mumford
hors
experi
first
infect
young
age
bryan
suffer
repeat
exposuresinfect
throughout
live
gener
consid
immun
infect
shortliv
height
durat
immun
respons
increas
reinfect
doll
major
problem
ehvi
serum
neutralis
antibodi
protect
reinfect
mumford
et
although
specif
compon
cellular
local
respiratori
tract
immun
develop
infect
relat
protect
unknown
natur
infect
ineffect
major
research
problem
design
immunoprophylact
measur
combat
ehvi
one
method
identifi
compon
equin
immun
respons
role
protect
target
investig
herpesvirus
speci
shown
specif
cellular
immun
gener
infect
stimul
cytotox
effector
cell
import
subsequ
protect
yasukawa
zarl
zuckermann
zsack
mettenleit
benporat
evid
accumul
import
mhc
restrict
cytotox
lymphocyt
cellular
immun
herpesvirus
speci
addit
classic
mhc
classi
restrict
cell
yasukawa
zarl
studi
cellular
immun
ehvi
base
mainli
cell
prolifer
assay
thomson
mumford
fitzpatrick
studdert
work
suggest
cytotox
lymphocyt
induc
primari
infect
edington
bridg
broad
grifith
typespecif
genet
restrict
cytotox
less
clear
secondari
infect
bridg
edington
v
cytotox
assay
depend
exogen
process
antigen
see
possibl
mhc
restrict
cytotox
effector
cell
respons
observ
activ
therefor
result
would
accord
find
human
herpesvirus
cellular
immun
domin
mhc
restrict
cytotox
lymphocyt
schmid
one
aspect
equin
immun
respons
requir
investig
identif
longterm
nonspecif
immunosuppress
hors
infect
hannant
ef
immunosuppress
long
durat
appear
relat
transient
numer
deficit
circul
lymphocyt
neutrophil
seen
ehvi
infect
mechan
unknown
may
affect
capac
anim
respond
infecti
agent
vaccin
sever
week
infect
although
transmit
via
respiratori
rout
viru
endotheli
cell
tropism
edington
bridg
patel
spread
throughout
bodi
cell
associ
viraemia
method
viru
transfer
foetu
mechan
induct
abort
understood
also
establish
latenc
reactiv
stress
edington
bridg
huckl
make
studi
immun
function
ehvi
difficult
cani
unfortun
overrid
problem
hinder
progress
studi
equin
cellular
immun
respons
ehvi
lack
reliabl
assay
equin
lymphocyt
function
marker
avail
differenti
equin
lymphocyt
subset
recent
first
intern
workshop
equin
leucocyt
antigen
set
coordin
characteris
monoclon
antibodi
reagent
equin
lymphocyt
kydd
antczak
p
time
articl
appear
antibodi
avail
identifi
varieti
equin
lymphocyt
subset
includ
descript
marker
excit
time
research
equin
immunolog
soon
possibl
differenti
major
type
equin
lymphocyt
purifi
particular
cell
detail
function
studi
exampl
monoclon
antibodi
equin
cd
marker
use
kill
inhibit
function
cytotox
lymphocyt
vitro
obrien
holm
duffu
lunn
expect
see
sever
import
public
within
next
month
answer
fundament
question
equin
immun
respons
ehvi
one
area
ehvi
research
made
great
progress
last
year
studi
molecular
biolog
detail
develop
beyond
scope
paper
profound
effect
develop
immunolog
briefli
viral
gene
code
import
viru
envelop
glycoprotein
isol
gene
product
express
bacteria
recombin
glycoprotein
use
vaccinia
viru
mani
studi
carri
intern
collabor
uk
ireland
usa
australia
part
collabor
examin
equin
cellular
immun
respons
one
particular
ehvi
glycoprotein
great
detail
studi
underway
dissect
equin
helper
lymphocyt
respons
small
fragment
peptid
glycoprotein
identifi
domin
peptidedpeptid
combin
gene
glycoprotein
sequenc
known
possibl
synthesis
multipl
peptid
encompass
protein
contain
within
entir
glycoprotein
molecul
peptid
prepar
kentucki
ship
newmarket
detail
studi
equin
lymphocyt
respons
underway
studi
molecular
biolog
immunolog
expens
mani
research
share
broad
object
import
research
ehvi
similar
collabor
natur
although
regular
use
inactiv
ehvi
vaccin
reduc
frequenc
abort
storm
breed
establish
evid
prevent
infect
mumford
bate
bryan
allen
circul
antibodi
produc
inactiv
live
attenu
ehvi
vaccin
rather
short
durat
describ
previous
high
level
antibodi
correl
protect
nonspecif
immunostimul
develop
hors
show
potenti
effect
treatment
clinic
ehvi
infect
leneau
steinmey
ragland
appropri
prevent
rhinopneumon
outbreak
influenza
viru
modem
approach
ehvi
immunoprophylaxi
focuss
system
best
potenti
stimul
cellular
humor
immun
iscom
technolog
examin
ehvi
experiment
vaccin
contain
defin
viru
glycoprotein
cook
et
al
produc
studi
progress
evalu
potenti
ehvi
iscom
vaccin
induc
humor
cellular
immun
hors
protect
challeng
infect
fig
immunolog
studi
benefit
advanc
molecular
biolog
equin
immun
respons
specif
ehvi
gene
product
better
understood
recent
studi
shown
one
import
viru
glycoprotein
ehvi
express
vaccinia
viru
recombin
properti
induc
neutralis
antibodi
protect
lethal
ehvi
infect
experiment
anim
model
guo
et
vaccinia
virusequin
influenza
viru
recombin
vaccin
next
logic
step
evalu
safeti
hors
studi
durat
immun
respons
protect
effici
littl
known
gener
durat
immun
equin
arter
viru
eav
mumford
serolog
survey
demonstr
presenc
eav
countri
far
isol
uk
ireland
although
transmiss
eav
usual
via
respiratori
rout
shown
high
percentag
stallion
shed
viru
semen
timoney
therefor
vener
transmiss
import
within
breed
establish
import
aspect
eav
biolog
longterm
chronic
carrier
state
exist
stallion
recov
clinic
viru
infect
timoney
et
exist
carrier
state
mare
less
certain
acut
system
diseas
caus
eav
infect
result
respiratori
diseas
paralysi
abort
mumford
ehvi
viru
spread
throughout
bodi
via
circulatori
system
replic
endotheli
cell
anim
recov
eav
infect
high
level
serum
virusneutralis
antibodi
induc
long
durat
high
level
antibodi
correl
well
protect
respiratori
vener
infect
mccollum
el
al
commerci
avail
live
attenu
eav
vaccin
licens
uk
induc
short
durat
serum
antibodi
stallion
although
vaccin
viru
never
isol
serum
urin
recov
sporad
blood
nasopharynx
vaccin
anim
timoney
umphenour
collum
fukanaga
er
shown
multipl
dose
inactiv
eav
vaccin
elicit
level
serum
antibodi
high
enough
prevent
clinic
diseas
protect
pregnant
mare
abort
challeng
virul
viru
even
though
clinic
diseas
avert
hors
high
antibodi
protect
infect
live
viru
recov
blood
sampl
valu
type
vaccin
control
diseas
within
stabl
unclear
known
vaccin
hors
show
reduc
level
viru
excret
nasopharynx
molecular
studi
provid
gene
sequenc
eav
identifi
major
viru
protein
de
vri
et
ul
den
boon
et
ul
hope
studi
exploit
examin
equin
immun
respons
defin
viru
antigen
way
possibl
target
domin
immun
respons
immunoprophylaxi
perhap
biggest
problem
face
thoroughbr
breed
race
industri
uk
advanc
singl
european
market
legisl
remov
mandatori
serolog
screen
import
hors
eav
risk
eav
infect
british
thoroughbr
increas
clinic
outbreak
would
difficult
control
proport
stallion
would
becom
viru
shedder
widespread
vaccin
programm
would
need
contain
spread
infect
major
research
effort
requir
develop
effect
vaccin
eav
mumford
current
one
research
group
work
viru
uk
equin
rhinovirus
classifi
within
picornaviru
famili
current
repres
three
serotyp
equin
rhinoviru
type
ervi
common
hors
popul
associ
clinic
subclin
respiratori
diseas
burrow
rare
associ
respiratori
diseas
except
young
anim
pathogenesi
often
compound
secondari
bacteri
infect
third
serotyp
describ
although
serolog
evid
infect
found
like
often
associ
diseas
studdert
gleeson
evid
long
term
carrier
state
equin
rhinovirus
pathogenesi
unclear
mumford
thomson
steck
et
detect
erv
seroconvers
often
coincid
viru
infect
ehvi
secondari
bacteri
infect
jolli
fu
robinson
matsumura
komano
sigiura
fu
kundga
mackintosh
grant
burrel
sugiura
matsumura
imagawa
fukunaga
high
incid
antibodi
erv
train
thoroughbr
stud
mare
burrow
jolli
et
u
sigiura
et
ul
necessarili
reflect
recent
infect
event
neutralis
antibodi
develop
quickli
infect
persist
anim
sever
month
case
year
burrow
per
cent
adult
hors
seroposit
jolli
e
long
term
immun
erv
infer
persist
neutralis
antibodi
relationship
antibodi
level
protect
diseas
known
doubt
rhinovirus
common
equin
pathogen
respons
respiratori
diseas
outbreak
young
thoroughbr
train
experiment
infect
model
need
develop
young
hors
typic
clinic
sign
viru
excret
reproduc
order
understand
function
immun
respons
equin
rhinovirus
mani
young
thoroughbr
race
stabl
experi
episod
respiratori
diseas
uncertain
caus
train
essenti
consid
multifactori
natur
equin
respiratori
diseas
diagnosi
treatment
howev
sometim
bacteri
infect
identifi
primari
caus
respiratori
diseas
hors
streptococci
import
group
streptococcu
equi
caus
agent
diseas
typic
form
induc
purul
nasal
discharg
inflamm
nasopharynx
abscess
adjac
lymph
node
two
clinic
form
equi
infect
atyp
catarrh
malign
bastard
strangl
todd
bacteri
virul
thought
associ
mlike
protein
stimul
format
antibodi
affect
anim
woolcock
studi
equin
immun
respons
equi
shown
resist
infect
appear
independ
level
bactericid
antibodi
serum
galan
timoney
relat
level
mucos
pharyng
immun
respons
protein
antigen
equi
exist
vaccin
strangl
compris
kill
organ
extract
presum
rich
mlike
protein
afford
littl
protect
mainli
high
level
serum
antibodi
stimul
pharyng
mucos
immun
respons
galan
timoney
timoney
egger
clear
immunoprophylaxi
strangl
hors
must
direct
toward
mucos
immun
novel
approach
use
recombin
dna
technolog
develop
avirul
strain
salmonella
carri
heterolog
antigen
stimul
mucos
immun
dougan
hormaech
maskel
oral
administr
typhirnuriurn
known
invad
prolifer
gutassoci
lymphoid
tissu
lead
develop
immun
respons
mucos
site
bienenstock
et
thu
equin
common
mucos
immun
system
exploit
much
way
inactiv
viru
vaccin
see
avirul
strain
typhirnuriurn
contain
protein
gene
equi
galan
timoney
curti
prepar
bacteria
express
high
level
protein
cultur
experi
progress
studi
potenti
immunogen
hors
safeti
aspect
import
equi
protein
involv
pathogenesi
purpura
haemorrhagica
galan
timoney
therefor
import
new
vaccin
stimul
protect
immun
strangl
without
increas
risk
immunecomplexrel
diseas
associ
protein
anoth
problem
must
address
strain
variat
equi
vaccin
one
strain
may
protect
anoth
galan
timoney
even
equi
one
equin
pathogen
mucos
immun
respons
known
domin
protect
techniqu
becom
avail
stimul
mucos
immun
directli
futur
look
good
effect
vaccin
pneumococc
infect
common
aetiolog
agent
commun
acquir
pneumonia
man
pneurnonia
one
princip
pathogen
gillespi
bacterium
isol
hors
sequel
respiratori
viru
infect
burrel
mackintosh
taylor
identifi
primari
pathogen
young
thoroughbr
train
mackintosh
et
date
equin
isol
capsul
type
benson
sweeney
pathogen
strain
austrian
gold
human
diseas
persist
carrier
pneurnonia
identifi
hors
mackintosh
era
two
major
compon
pneurnonia
antibodi
produc
human
respons
infect
vaccin
capsular
polysaccharid
cp
cell
wall
compon
known
cpolysaccharid
antibodi
cp
consid
essenti
surviv
anim
challeng
lethal
dose
virul
pneumococci
gillespi
antibodi
cpolysaccharid
found
suscept
speci
therefor
protect
antibodi
cp
advantag
common
serotyp
current
identifi
antibodi
product
cp
regul
suppressor
cell
special
type
amplifi
cell
stimul
antigenspecif
b
cell
undergo
addit
round
prolifer
therebi
increas
amount
antibodi
produc
taylor
et
ul
braleymullen
noth
known
rel
import
humor
cellular
immun
pneurnonia
hors
howev
sever
lead
medic
research
experiment
anim
studi
follow
develop
rapid
serolog
diagnost
test
effect
vaccin
serolog
use
routin
diagnos
pneurnonia
serotyp
man
gillespi
capsular
antigen
may
detect
serum
urin
patient
pneumococc
pneumonia
serotypespecif
latex
agglutin
test
oneil
et
serolog
diagnosi
pneurnoniu
report
rare
hors
mackintosh
eta
current
research
direct
toward
develop
test
suitabl
serosurvey
preval
pneurnoniu
thoroughbr
j
wood
hannant
unpublish
data
inform
help
identifi
frequenc
asymptomat
persist
carrier
high
level
antibodi
cp
correl
protect
speci
gillespi
evid
respiratori
tract
antibodi
protect
infect
pneurnonia
although
mucos
immun
import
protect
equi
streptococc
infect
czerkiski
et
therefor
appear
gener
durat
antibodi
respons
cp
offer
best
first
approach
target
effect
vaccin
pneurnoniu
hors
particularli
import
cellular
immun
respons
seem
relat
regul
antibodi
cp
rhodococcu
equi
first
isol
foal
fatal
pneumonia
magnusson
main
rout
infect
respiratori
alimentari
genit
anim
develop
clinic
diseas
alimentari
rout
one
foal
acquir
subclin
infect
result
stimul
humor
cellular
immun
prescott
ogilvi
markham
hietala
ardan
sansom
respiratori
rout
infect
like
caus
progress
pulmonari
lesion
associ
r
equi
pneumonia
foal
zink
yager
prescott
fernando
suggest
r
equi
caus
pneumonia
foal
persist
intracellular
infect
alveolar
macrophag
pneumonia
induc
r
equi
usual
restrict
foal
older
hors
immunocompromis
suffer
concurr
infect
also
affect
neither
healthi
adult
hors
yager
foal
young
three
week
age
machang
u
prescott
sever
attempt
made
protect
foal
r
equi
infect
use
inactiv
bacteria
bacteri
extract
vaccin
although
immun
respons
demonstr
treat
anim
evid
protect
woolcock
mutim
bowl
machang
u
prescott
passiv
immunis
newborn
foal
ingest
colostrum
immunis
mare
fail
protect
r
equi
infect
seven
day
later
marten
marten
fisk
p
also
intraven
infus
immun
plasma
foal
seven
day
experiment
infect
show
immunoprophylact
advantag
chafin
marten
marten
fisk
p
howev
immun
plasma
provid
protect
r
equi
given
foal
two
four
day
prior
experiment
infect
marten
marten
fisk
hietala
find
suggest
immunolog
benefit
immun
plasma
obviou
earli
stage
diseas
prior
establish
sever
pulmonari
infect
therefor
although
natur
exposur
vaccin
induc
specif
immun
respons
foal
difficult
gaug
protect
role
immun
also
contribut
local
respiratori
tract
immun
protect
recoveri
r
equi
unknown
clearli
urgent
need
identifi
function
antigen
specif
immunolog
respons
pathogen
hors
start
develop
potenti
vaccin
orher
common
respiratori
bacteria
mackintosh
et
isol
aerob
nine
oblig
anaerob
bacteri
speci
young
thoroughbr
hors
seven
consid
potenti
pathogen
viz
zooepidemicu
pneumonia
bordetella
bronchisepticu
pasreurella
pneumotropica
p
huemolyrica
peptostreptococcu
spp
fusohacterium
spp
episod
bacteri
infect
may
preced
clinic
subclin
infect
respiratori
virus
result
infect
compromis
host
therefor
take
signific
role
pathogenesi
lower
airway
diseas
exampl
zooepidemicu
routin
isol
respiratori
tract
healthi
hors
also
associ
respiratori
diseas
whitwel
greet
clear
bacteri
pathogen
equin
respiratori
tract
function
primari
agent
diseas
littl
known
import
immun
respons
new
develop
immunolog
molecular
biolog
affect
control
infecti
diseas
hors
futur
initi
would
appear
live
attenu
vaccin
recombin
viralbacteri
vaccin
offer
best
chanc
stimul
strong
immun
respons
respons
level
achiev
natur
infect
occur
without
associ
patholog
damag
although
scenario
attract
number
fundament
appli
problem
may
delay
univers
adopt
type
technolog
firstli
larg
amount
basic
research
need
done
identifi
import
antigen
express
recombin
vaccin
vector
moreov
immun
respons
stimul
one
alreadi
identifi
import
protect
recoveri
alreadi
seen
gener
high
level
circul
antibodi
may
littl
relev
gener
immun
secondli
desir
antigen
target
appropri
express
recombin
vaccin
system
import
know
vector
accept
target
speci
thoroughbr
hors
side
reaction
associ
use
vaccinia
pox
viru
vector
may
limit
use
techniqu
one
problem
possibl
sever
reaction
secondaryhoost
inject
immun
respons
vaccinia
viru
strong
fear
immun
vaccinia
viru
within
equin
popul
increas
would
inappropri
reaction
second
inject
therefor
recombin
vaccin
would
need
good
enough
stimul
longterm
immun
singl
vaccin
would
happen
vaccinia
recombin
vaccin
use
produc
immun
one
equin
pathogen
necessari
revaccin
later
anoth
equin
pathogen
use
vaccinia
recombin
system
mean
vaccin
need
polyval
carri
anticip
antigen
produc
lifelong
immun
one
inocul
recent
studi
experiment
anim
show
preexist
immun
vaccinia
viru
detriment
protect
influenza
andrew
herp
simplex
viru
rooney
ef
al
induc
vaccinia
recombin
vaccin
former
studi
also
show
invers
relationship
level
preexist
immun
viral
vector
time
immunis
level
protect
induc
recombin
vaccin
passiv
immun
transfer
immun
serum
suppress
immun
respons
vaccinia
viru
recombin
johnson
meiten
bender
small
brochier
er
littl
known
perform
recombin
vaccin
anim
cover
matern
antibodi
deriv
colostrum
rapid
progress
molecular
biolog
equin
virus
last
year
soon
inform
safeti
efficaci
recombin
viru
vaccin
import
pathogen
eg
influenza
ehvi
safeti
problem
overcom
show
great
potenti
new
strain
equin
influenza
recent
identifi
china
webster
yuanji
unusu
possibl
spread
hors
directli
bird
without
genet
reassort
lost
abil
replic
duck
viru
probabl
spread
migrat
water
bird
molecular
technolog
avail
analys
import
antigen
strain
ensur
inclus
new
vaccin
develop
valu
specif
target
immun
respons
emphasisi
diseas
effect
immun
identifi
function
one
compon
immun
system
soon
new
adjuv
method
present
vaccin
immun
system
like
widespread
equin
world
advent
iscom
technolog
allow
develop
subunit
vaccin
use
hors
influenza
ehvi
commerci
potenti
underdevelop
area
specif
target
immun
respons
site
infect
take
place
although
potenti
stimul
mucos
surfac
inactiv
live
attenu
vaccin
identifi
mani
method
examin
liposom
iscom
present
viralhacteri
antigen
nasopharynx
one
method
potenti
hors
equin
immun
respons
import
respiratori
pathogen
dissect
cellular
molecular
term
great
progress
made
identif
import
compon
function
activ
turn
advanc
understand
viralhacteri
structur
function
reveal
import
antigen
like
stimul
antibodi
cellular
immun
respons
collabor
studi
main
studi
centr
equin
immunolog
virolog
bacteriolog
patholog
begin
show
import
result
signific
advanc
expect
within
next
year
